ImmunityBio, Inc. (IBRX) shares tumbled 17.7% to $7.11 as of November 9, 2026, a sharp decline from the prior close of $8.64. BestStocks flagged the session as a major change for IBRX. The move is tied to an earnings miss. Below, we break down what changed for IBRX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Earnings Miss
ImmunityBio, Inc. (IBRX) reported EPS of −$0.18 vs. −$0.07 consensus estimate, missing by 157.1% on 2026-11-09. IBRX's next earnings are scheduled for 2027-03-02 (date not yet confirmed) with consensus EPS estimate of −$0.07.
This summary describes the catalyst and move as first detected on Nov 9, 2026, 10:13 AM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsHigh confidence
Rel. volume
3.0×
Extreme
Vs peers
—
No comparable peers
Market cap
$7.5B
NASDAQ Global Select
Analyst target
$15
+111.1% vs price
Price chart
Oct 9 – Nov 9
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for ImmunityBio, Inc. investors
For ImmunityBio, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Earnings missed expectations; Sharp 17.7% decline — elevated risk. Wall Street's consensus price target sits at $15.00, implying +111.1% upside from $7.11. BestStocks rates the overall signal quality high (90/100). With earnings roughly 113 days out, the next report is the most likely near-term test of the move.
IBRX price reaction
IBRX last traded at $7.11, down $1.53 (-17.72%) from the previous close of $8.64. The session traded on 3.0× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $7.11 and $10.51, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on ImmunityBio, Inc. (IBRX)
▼Latest catalyst·a bearish counterpoint
The latest catalyst — an earnings miss — a bearish counterpoint that challenges the prevailing bullish analyst view.
The consensus analyst price target on ImmunityBio, Inc. (IBRX) is $15.00, 111.1% above the recent $7.11. Over the past 90 days analysts logged 0 upgrades, 2 maintains, and 0 downgrades. Here is how the bullish and bearish cases on IBRX line up.
▲ The bullish case
+Wall Street's consensus price target of $15.00 implies +111.1% upside from $7.11.
+The Street's most bullish target is $16.00 (+125.2%).
+Positive price momentum.
▼ The bearish case
−Earnings missed expectations.
−Sharp 17.7% decline — elevated risk.
−High volume 3.0x on decline — distribution signal.
−ImmunityBio reported Q3 2026 results with net product revenue of $48.7 million (up 53% YoY) and first-nine-months U.S. revenue up 92% to $143.6 million, alongside label expansion and Israeli Ministry of Health approval of ANKTIVA® Plus BCG; however, the company reported a Q3 loss and missed revenue estimates (per Zacks).
−ImmunityBio shares fell 4.50% to $7.85, driven by profit-taking and valuation concerns following a multi-month rally, according to market analysis cited by Yahoo Finance.
Bull vs bear balanceStrong Bearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 9, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
ImmunityBio reported Q3 2026 results with net product revenue of $48.7 million (up 53% YoY) and first-nine-months U.S. revenue up 92% to $143.6 million, alongside label expansion and Israeli Ministry of Health approval of ANKTIVA® Plus BCG; however, the company reported a Q3 loss and missed revenue estimates (per Zacks). The stock fell 21.24% to $6.80 on elevated volume of 26.99 million shares (10.29x the typical intraday average at this time).
Filings2026-11-09-17.8%
ImmunityBio, Inc. (IBRX) filed its 10-Q on November 9, 2026. The quarterly filing does not indicate a stock price move.
Material / Earnings2026-11-06+7.9%
ImmunityBio, Inc. (IBRX) moved +5.69% from $8.17 to $8.63 on 2026-11-06 after initiating European patient treatment with ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer.
News2026-11-05-10.3%
ImmunityBio, Inc. (IBRX) moved −8.77% from $8.78 to $8.01 on November 5, 2026. We checked news, earnings announcements, analyst updates, and SEC filings — no company-specific catalyst was found on or immediately before this date. The company did initiate European patient treatment with ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer, but this was reported separately. Volume was 1.5× the 5-day average, suggesting modest institutional activity.
News2026-11-04+7.7%
IBRX initiated European patient treatment with ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer.
News2026-11-04+7.7%
ImmunityBio, Inc. (IBRX) moved +6.06% on November 4, 2026, after the company treated its first European patients with ANKTIVA plus BCG in Germany and Austria. The launch follows European Commission conditional marketing authorization for ANKTIVA in combination with BCG to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer. ImmunityBio is executing the European rollout through partnerships with Accord Healthcare for market access and Uniphar for supply chain and distribution.
ImmunityBio gained 7.57% to $8.40 after Davidson Kahn Capital Management LLC trimmed its stake in the company, according to defenseworld.net. Volume stands at 3.3M shares (0.82x normal for this time of day), suggesting modest participation behind the move.
ImmunityBio shares fell 4.50% to $7.85, driven by profit-taking and valuation concerns following a multi-month rally, according to market analysis cited by Yahoo Finance. The decline reflects caution ahead of upcoming QUILT-2.005 trial topline results expected in November 2026, with investors reassessing the stock's stretched valuation relative to current revenue despite recent FDA approval expansion for ANKTIVA in bladder cancer.
In-depth IBRX event analyses
Permanent, dated analyses of IBRX's most significant sessions.
IBRX tumbled 17.7% to $7.11. The move is associated with an earnings miss.
How much did IBRX stock fall?
IBRX lost 17.72% ($1.53) versus the prior close of $8.64, last trading at $7.11 on 3.0× average volume.
When is ImmunityBio, Inc.'s next earnings date?
IBRX's next earnings report is estimated for 2027-03-02 — about 113 days away.
What is the analyst price target for IBRX?
The consensus analyst price target for IBRX is $15.00, about 111.1% above the current $7.11. Over the past 90 days, analysts recorded 0 upgrades, 2 maintains, and 0 downgrades.
How BestStocks tracks IBRX
This page is generated automatically by BestStocks' change-detection system after an earnings miss was detected and verified against independent data sources. It draws on 20 tracked change events for IBRX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 9, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
